MKI67 and neoplasm: Multivariable analysis showed that post-menopause (HR 2.33, 95% CI: 1.69–3.22, P <  0.001), neo-adjuvant therapy (HR 2.39, 95% CI: 1.61–3.56, P <  0.001), tumor > 2.0 cm (HR 1.81, 95% CI: 1.32–2.48, P <  0.001), positive ALNs (HR 2.15, 95% CI: 1.97–2.93, P <  0.001), grade III (HR 1.69, 95% CI: 1.19–2.40), and Ki-67 ≥ 14% (HR 1.43, 95% CI: 1.02–2.00, P = 0.037) were associated with worse OS, while ER ≥ 50% (HR 0.44, 95% CI: 0.24–0.78) and endocrine therapy (HR 0.46, 95% CI: 0.30–0.71, P <  0.001) were associated with significantly better OS (Table 3).